This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Beyond 076

Nathan Shaffer, MD

JAMA. 2001;285:2129-2131.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Since 1994, rapid implementation of the landmark ACTG 076 study regimen has led to a dramatic reduction in perinatal HIV (human immunodeficiency virus) transmission in the United States and other developed countries.¹ Cohort studies, registries, and surveillance data have all confirmed the effectiveness of the 3-part zidovudine monotherapy regimen, administered orally to the pregnant woman beginning at 14 to 34 weeks' gestation, intravenously during labor, and orally to the newborn for 6 weeks. In the absence of breastfeeding, use of this regimen has resulted in perinatal transmission rates of 4% to 10% in the United States and Europe.² In conjunction with the 076 regimen, elective caesarean delivery or combination antiretroviral therapy has resulted in transmission rates of less than 2%.^2-4 Although the data on combination therapy have been quite limited, there is a growing conviction that perinatal HIV transmission can be reduced to near zero with early . . . [Full Text of this Article]

Author Affiliations: MTCT Unit, Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, Ga.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1
Laurent Mandelbrot, Aline Landreau-Mascaro, Claire Rekacewicz, Alain Berrebi, Jean Louis Bénifla, Marianne Burgard, Eric Lachassine, Béatrice Barret, Marie-Laure Chaix, André Bongain, Nicole Ciraru-Vigneron, Catherine Crenn-Hébert, Jean-François Delfraissy, Christine Rouzioux, Marie-Jeanne Mayaux, Stéphane Blanche, and for the Agence Nationale de Recherches sur le SIDA 075 Study Group
JAMA. 2001;285(16):2083-2093.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Routine antenatal HIV testing and informed consent: an unworkable marriage?
Bennett
J. Med. Ethics 2007;33:446-448.
FULL TEXT  

The Impact of Expected HIV Transmission Rates on the Effectiveness and Cost of Ruling Out HIV Infection in Infants
Mrus et al.
Med Decis Making 2002;22:S38-S44.
ABSTRACT  

Management of Human Immunodeficiency Virus Infection in Pregnancy
Watts
NEJM 2002;346:1879-1891.
FULL TEXT  

Role of traditional birth attendants in preventing perinatal transmission of HIV Commentary: Involving traditional birth attendants in prevention of HIV transmission needs careful consideration
Bulterys et al.
BMJ 2002;324:222-225.
FULL TEXT  

Two Drugs for HIV Prevention: More Benefit, More Risk
JWatch Gastroenterology 2001;2001:11-11.
FULL TEXT  

AZT + 3TC in Pregnancy
AIDS Clin Care 2001;2001:3-3.
FULL TEXT  

Two Drugs for HIV Prevention: More Benefit, More Risk
JWatch General 2001;2001:7-7.
FULL TEXT